试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.
研究概览
简要总结
The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.
详细描述
This retrospective analysis of physician prescribing data (long-term concessional cohort from the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol 500mg in a cohort of Australian concessional patients with OA, to assess differences in prescribing patterns and patient compliance.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants prescribed with a paracetamol product and categorized as a concessional patient
- •Participants with new episodes of OA (no history of OA paracetamol in previous 12 months) or suffering from chronic OA (history of OA paracetamol in the previous 12 months)
排除标准
- •Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions
- •Participants receiving the following anti-rheumatoid therapies:Immunimodulators such as methotrexate, leflunamide and TNF blockers
- •Participants receiving treatment for cancer pain
研究组 & 干预措施
Extended Release Paracetamol
Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
干预措施: Paracetamol 665 mg (Drug)
Standard Paracetamol
Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
干预措施: Paracetamol 500 mg (Drug)
结局指标
主要结局
Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.
时间窗: January 2009 to December 2010
Number of episodes of treatment for OA with the extended release formulation and the standard release formulatins will be counted.
Relative treatment compliance with an extended release paracetamol formulation and a standard release paracetamol formulation
时间窗: January 2009 to December 2010
Interval between the repeat doses of extended release paracetamol formulation and the standard release paracetamol formulation.
次要结局
未报告次要终点